Ligacim Bio

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • KRW 57.4B put option liability reclassified as equity deduction due to Iksuda Therapeutics Limited control acquisition in FY2025
• • FY2025 removal of KRW 17.0B derivative liability related to prior Iksuda Therapeutics Limited forward share contracts

Management Discussion & Analysis

• • Revenue KRW 141.6B (+12.4% YoY), operating loss KRW 10.6B (-409%), net loss KRW 9.2B vs net income KRW 0.78B prior year
• • Technology licensing revenue KRW 121.2B (+15%) drove growth, attributed to patent-protected proprietary linker and payload technologies

Business Overview

• • ADC platform "ConjuALL" technology with multiple global licensing deals totaling approx. KRW 9.4T milestone secured in FY2025
• • FY2025 technology transfer revenue KRW 1.21T from ADC candidates and platform, up from KRW 1.05T in 2024

What are the latest Ligacim Bio DART filings in 2026?

Ligacim Bio (KRX code 141080) has filed an annual report on March 23, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Ligacim Bio file its most recent annual report?

Ligacim Bio filed its most recent annual report on March 23, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Ligacim Bio's KRX stock code?

Ligacim Bio's KRX stock code is 141080. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 141080 to look up all Ligacim Bio disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Ligacim Bio file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Ligacim Bio.

Where can I find Ligacim Bio financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Ligacim Bio annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.